Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-MOMIPP (3-(6-methoxy-2-methyl-1H-indol-3-yl)-1-(4-pyridinyl)-2-propene-1-one) is a synthetic indole-based chalcone that acts as a potent microtubule-disrupting agent. Developed by researchers at the University of Toledo, it is a structural isomer of 5-MOMIPP. While 5-MOMIPP induces a non-apoptotic cell death called methuosis, 6-MOMIPP causes rapid disruption of microtubules by competing for the colchicine-binding site on tubulin. This leads to mitotic arrest and subsequent caspase-independent cell death. 6-MOMIPP has shown high potency against glioblastoma and melanoma cell lines in vitro and demonstrates the ability to cross the blood-brain barrier in murine models, suggesting potential utility in treating primary and metastatic brain tumors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-MOMIPP.